For the second episode of season 2 of Phacilitate Talks, we interrupt planned transmission to discuss the future of AAV with Nicole Paulk, following the recent FDA AdComm. Welcome to the second episode of season 2 of Phacilitate Talks! This week, we interrupt planned transmission to discuss the future of AAV following the FDA AdComm in early September. Watch the full episode via the Phacilitate website: https://bit.ly/3hrQVP3 As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.  Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG  In this second episode, Anthony and Georgi are joined by Nicole Paulk, AAV Gene Therapy Professor at UCSF, as they discuss reactions to the AdComm meeting, and what we should expect from AAV in the future. The group discusses a perhaps unfair perception of AAV, novel technologies poised to advance the field, empty capsids, and what guidance is needed to help progress AAV. QUICK LINKS Nicole Paulk: https://bit.ly/3k65vxA  Anthony Davies: https://bit.ly/3B7EQpJ  Christina Fuentes: https://bit.ly/2YSihaL  Georgi Makin: https://bit.ly/3jbg5Tj  The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers. This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/